<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889069</url>
  </required_header>
  <id_info>
    <org_study_id>ML28881</org_study_id>
    <secondary_id>2013-000647-12</secondary_id>
    <nct_id>NCT01889069</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)</brief_title>
  <official_title>A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic
      (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of
      differentiation 20 positive (CD20+) DLBCL or FL. In addition to standard chemotherapy,
      participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the
      Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during
      the Maintenance period.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2013</start_date>
  <completion_date type="Anticipated">June 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Administration-Associated Reactions (AAR)</measure>
    <time_frame>Baseline up to 54 months</time_frame>
    <description>AAR is defined as all related adverse events (AEs) occurring within 24 hours of rituximab SC administration, including infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. AE is defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with AEs</measure>
    <time_frame>Baseline up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) According to International Working Group (IWG) Response Criteria</measure>
    <time_frame>Day 1 up to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first (up to maximum 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to IWG Response Criteria</measure>
    <time_frame>Day 1 up to first occurrence of progression or relapse, or death, whichever occurs first (up to maximum 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Day 1 until death (up to maximum 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) According to IWG Response Criteria</measure>
    <time_frame>From 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occurs first (up to maximum 54 months) (end of Induction period = up to 8 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Complete Response (CR) According to IWG Response Criteria</measure>
    <time_frame>At 4 to 8 weeks after end of Induction period (end of Induction period = up to 8 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FL: Plasma Concentration of Rituximab</measure>
    <time_frame>Induction: predose (0 hour) on Day 1 Month 1, and predose (0 hour) on Day 1 Month 8; Maintenance: predose (0 hour) on Day 1 Month 1, and predose (0 hour) on Day 1 Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL: Plasma Concentration of Rituximab</measure>
    <time_frame>Induction: predose (0 hour) on Day 1 Month 1, predose (0 hour) on Day 1 Month 7, Day 7 Month 7, Day 14 Month 7; predose (0 hour) on Day 1 Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab</measure>
    <time_frame>Induction: predose (0 hour) on Day 1 Month 1, predose (0 hour) on Day 1 Month 7, Day 7 Month 7, Day 14 Month 7; predose (0 hour) on Day 1 Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab</measure>
    <time_frame>Induction: predose (0 hour) on Day 1 Month 1, predose (0 hour) on Day 1 Month 7, Day 7 Month 7, Day 14 Month 7; predose (0 hour) on Day 1 Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL: Apparent Total Clearance (CL/F) of Rituximab</measure>
    <time_frame>Induction: predose (0 hour) on Day 1 Month 1, predose (0 hour) on Day 1 Month 7, Day 7 Month 7, Day 14 Month 7; predose (0 hour) on Day 1 Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Responses to Rituximab Administration Satisfaction Questionnaire (RASQ)</measure>
    <time_frame>Baseline up to 24 months (assessed at enrollment [Day 1]; Induction: at the end of induction [Month 8]; Maintenance: at the end of Maintenance [Month 24])</time_frame>
    <description>Patient-assessed satisfaction will be evaluated using RASQ. Participants will be asked questions regarding convenience and satisfaction for rituximab SC. Percentage of participants by responses to individual questions will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>MabThera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, CD20+ DLBCL or CD20+ follicular non-Hodgkin's lymphoma (NHL)
             Grade 1, 2 or 3a, according to the World Health Organization (WHO) classification
             system

          -  Currently being treated with rituximab intravenously (IV) in the Induction or
             Maintenance period, having received at least one full dose of rituximab IV, defined as
             standard full dose of rituximab IV 375 milligrams per square-meter (mg/m^2)
             administered without interruption or early discontinuation (i.e. tolerability issues)

          -  Expectation and current ability for the participant to receive at least 4 additional
             cycles of treatment during the Induction period or 6 additional cycles of treatment
             during the Maintenance period (participants with follicular NHL)

          -  An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with bulky
             disease, defined as one lesion greater than or equal to (&gt;=) 7.5 centimeters (cm), or
             Follicular Lymphoma International Prognostic Index (FLIPI) (low, intermediate or high
             risk) assessed before the first rituximab IV administration in Induction period

          -  At least one bi-dimensionally measurable lesion defined as &gt;=1.5 cm in its largest
             dimension on computed tomography (CT) scan

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             (&lt;=) 3

        Exclusion Criteria:

          -  Transformed lymphoma or FL IIIB

          -  Primary central nervous system lymphoma, histologic evidence of transformation to a
             Burkitt lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the
             testis, or primary cutaneous DLBCL

          -  History of other malignancy

          -  Ongoing corticosteroid use greater than (&gt;) 30 milligrams per day (mg/day) of
             prednisone or equivalent

          -  Inadequate renal, hematologic, or hepatic function

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies or known sensitivity or allergy to murine products

          -  Contraindications to any of the individual components of standard chemotherapy

          -  Other serious underlying medical conditions, which, in the Investigator's judgement,
             could impair the ability of the participant to participate in the study

          -  Recent major surgery (within 4 weeks prior to dosing, other than for diagnosis)

          -  Active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, or human
             immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irccs Crob</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Basilicata</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi-Melacrino-Morelli; Unità Operativa di Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S.G. Moscati; Divisione Ematologia</name>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl ce - p.o. Avers; Uoc ematologia</name>
      <address>
        <city>Aversa</city>
        <state>Campania</state>
        <zip>81031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Sebastiano; U.O.C. Oncologia</name>
      <address>
        <city>Caserta</city>
        <state>Campania</state>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Santa Maria Goretti; Ematologia</name>
      <address>
        <city>Latina</city>
        <state>Lazio</state>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Eugenio; Divisione Di Ematologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina Elena National Cancer Institute; Hematology</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giovanni Addolorata; UOC Ematologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Viterbo; Presidio Ospedaliero di Ronciglione; UOC Ematologia</name>
      <address>
        <city>Ronciglione</city>
        <state>Lazio</state>
        <zip>01037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce;U.O.S. Oncologia Ed Ematologia</name>
      <address>
        <city>Como</city>
        <state>Lombardia</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST DI CREMA; U O Oncologia Medica</name>
      <address>
        <city>Crema</city>
        <state>Lombardia</state>
        <zip>26013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST DI LECCO; Oncologia Medica</name>
      <address>
        <city>Lecco</city>
        <state>Lombardia</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Carlo Poma; Divisione Di Oncologia Medica</name>
      <address>
        <city>Mantova</city>
        <state>Lombardia</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. San Raffaele; Dip. Di Oncoematologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Policlinico San Matteo; Divisione Di Ematologia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia</name>
      <address>
        <city>Ascoli Piceno</city>
        <state>Marche</state>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Civitanova Marche; Medicina Interna</name>
      <address>
        <city>Civitanova Marche</city>
        <state>Marche</state>
        <zip>62012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Macerata; Medicina Generale</name>
      <address>
        <city>Macerata</city>
        <state>Marche</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia</name>
      <address>
        <city>Campobasso</city>
        <state>Molise</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.&amp; Ircad</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera oo rr di foggi; Hematology</name>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Nicola Pellegrino; Reparto Di Ematologia</name>
      <address>
        <city>Trani</city>
        <state>Puglia</state>
        <zip>70059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Roberto Binaghi; Centro trapianti di midollo osseo</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. San Francesco; Ematologia e CTMO</name>
      <address>
        <city>Nuoro</city>
        <state>Sardegna</state>
        <zip>08100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARNAS Garibaldi; Ematologia</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Papardo; Struttura Complessa Di Ematologia</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara; Unita Operativa Di Ematologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USL 4 di Prato - Nuovo Ospeale di Prato</name>
      <address>
        <city>Prato</city>
        <state>Toscana</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria Terni; S.C. Oncoematologia</name>
      <address>
        <city>Terni</city>
        <state>Umbria</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

